In a country where heart attacks show up uninvited at weddings, office meetings, and morning walks, it’s no longer a problem reserved for the old. And while most of us keep blaming butter chicken and stress, a new drug is making global headlines — and it’s worth our attention.
Meet Lepodisiran, a promising experimental injection that targets a tricky little villain in our blood called Lp(a) or lipoprotein(a). Most of us have never heard of it, but if you’ve lost someone to a sudden heart attack despite normal cholesterol levels, Lp(a) might have been the hidden culprit.
Lepodisiran drug shows unprecedented 94% drop in heart disease risk factor: Study
What makes this drug headline-worthy? One shot could dramatically slash these stubborn Lp(a) levels for nearly a year — a massive leap for people genetically predisposed to heart disease, especially in South Asian populations known for higher cardiac risks at younger ages.
It’s still early days, but the excitement is real. While India battles rising heart attack rates in 30- and 40-year-olds, innovations like Lepodisiran could become game-changers in prevention, not just treatment. And considering how often we neglect preventive care until the ECG says otherwise, this might be a wake-up call we actually listen to.
Because in a country where heart disease isn't just a medical issue but a family one, anything that helps us hold on to our people a little longer deserves a spot in the conversation.